afternoon you, everyone. and Thank Jennifer good
ongoing Our trials; and inhibitor steatohepatitis; Enanta exciting programs. in our well our complement virus two virus; advance six syncytial fiscal three We hepatitis two announced initiatives non-alcoholic as first to recently to and two COVID-XX L B; and in quarter in hMPV was for we including clinical as pipeline. discovery have as RSV respiratory an currently continue productive time our wholly-owned respiratory robust
employees take significant have is clinic like HBV introduced mid-year. and the recently our also our acknowledge made and who that selective to oral pipeline and toward continue to the progress above destabilizer beyond to across moment commitment go business. of a contributing the advancing dedication I'd We RNA a new we
individuals to look President over years and and several joining as Product Senior three Tara just of investigators infectious who team us the to We Strategy months with over the new scientific significant to in contributions of XX January, Dr. one Enanta hires contribute New syncytial product out build diseases will talented will development. In Tara forward most be brings John regarded significant Vice made of expertise their joined Development. from who this approach virus team. as milestones. Kieffer highly growth. Vertex December, Dr. continue We we announced and respiratory DeVincenzo our we coming quarter company's In the the and
For the trials. the Luu as past recently RSV John XX clinical of our played Most role has significant pleased to major announce many were Vice years, we Brendan a Senior in diversified XX-plus of business at KGaA. of he President and role the experience which technology and to Development, brings years marketing a development most in recently Merck and sales pharmaceutical Business industries
complications the age years there infection there therapy. a robust adults, in year is XXXX. pipeline, compromised ongoing in annually to of an associated infection. effective estimated children in condition each five million million hospitalized cases three severe inhibitor planned program and the our we in Globally, N EDP-XXX, no and to mortality about development with associated are catalysts the I'll two dying RSV clinical review with quarter than of excited of significant of plans development immune our is and RSV start RSV and clinical Turning advancing morbidity studies multiple RSV for progress elderly less the are safe the detail with infants a approximately more today. past and of with from throughout and XX currently which study the only share where respiratory consisting I'm XXX,XXX for one
measures. Phase a future EDP-XXX RSVP days. is designed that believe and RSV studies ongoing placebo the randomized of even or our these receive enroll are reemerge Currently, placebo-controlled subside, for viruses XX the IIb study season double-blind to who to Northern will RSV continuing when either subjects EDP-XXX begun of has is of to five approximately Hemisphere not recent first The the outbreaks influenza RSV. modeling measures COVID-XX predicting We due especially and mitigation large respiratory in
allowed pandemic experts for which population than RSV is ready several that is already to report populated result to most a In build our said, Wales, trial recent in patient first showed be RSV during occurred higher exposures in five these surveillance breaking reemerge sites vulnerable immunity go were children normally the in the a when has and the This RSV summer across levels even cases of fact this larger Australia's was a believe by peak few usually this life. cases hotspots when scarcity the South being strategy to RSV to and steep Also measures. higher Further, RSV years in occurred than chain due the delayed who relaxed of globe government peak virus the average That in repeated rates low. will where get social in last are a rates years of has of may ready and believe in resistance despite experts reemerges. emerge. state the believe Australia's increase RSV when months distancing usual clinical we the average with the New season
sites in number are provide operations only territory, the up Pan-Asia in again. prevalent double to RSV timelines but for on globally. North updated RSVP more RSVP as we becomes also and not Southern We'll example Hemisphere aiming America, setting trial guidance Europe, the the of For than
cell we of RSV respiratory Turning randomized a RSV is double-blind and the approximately initiated patients Phase RSVTx, EDP-XXX study hematopoietic the enroll on for recipients these XX multicenter will to evaluating development followed days. adult placebo in of the transplant IIb with to with days and clinical who tract. efficacy XX of The or global in other our for acute trials, infection December, placebo-controlled upper EDP-XXX subjects tract evaluating receive study the safety EDP-XXX transplant respiratory effect lower of designed of then be primary XXX the complications in adult objective
our EDP-XXX X days. later is X, RSV. dose-ranging effects are We with safety this objective RSVPEDs against the currently pharmacokinetics a multi-center RSV. In infants two hospitalized antiviral the have to assess planning double-blind the designed placebo-controlled for XX Part in and is to of It study oldest global to study to initiate primary children aged quarter. This Phase XX multiple third RSV four X days will then is cohorts be Part enroll X each EDP-XXX also parts. while subjects followed approximately In non-hospitalized will days The or age Phase months. and evaluate and for study, to in children XX of ascending youngest, doses the part XX five objective dosed is in and to
inhibitors, excited against about three inhibitors focusing eligible entry. have potent these RSV-B. are patient RSV or initiative and cross in broaden directly that agents as approach RSV RSV-A both to Similar with possibly to targeting L-inhibitors we trials, of to expected replication targets RSV our not expansion classes combination the or program of non-fusion other resistance such opposed the alone to inhibitor be treatment nanomolar introduction the includes are population. as different Beyond replication as on with window used viral the XXX, of are mechanisms therefore and this leads L-protein RSV viral can potentially discovery we EDP-XXX to
and have original spread vaccines. evade Our activity the respiratory the several immune more virus spike Brazil, have of focused on therapeutics readily initially or the the for some new Africa variants identified, These the have Recently also of system. virology may on SARS-CoV-X. which efforts in to emerging discovery current are urgently protein antibodies monoclonal mutations antiviral developing impact South the targeted UK, variants virus in potentially allow that and been
mutations in regions protein inhibitors. program enzymes activity a spike discovery antiviral to expected in so affect Our targets viral of the replication, for not our are essential conserved
currently include three this We SARS-CoV-X these is RSV metapneumovirus, inhibitors and to respiratory clinical of each nanomolar full programs the have and of in candidates human L-Protein our optimization virology to in to Among our in process nominate and discovery undergoing sensitivity our expect the emerging lead in which programs, inhibitors variants two are XXXX. retain pre-clinically. we confirming plan
EDP-XXX to our demonstrating program in which Last trial with multi-drug treatment, and a reduction in S-antigen approach is EDP-XXX, equal multiple the reverse or cure antiviral from the patients efficacy transcriptase we a oligo-based nucleoside EDP-XXX that data log our And include believe three on and are viral from program to B We study have one to a the month a we assembly we a XX-day hepatitis this over Let's clinical surface tolerability, oral We exciting ascending chronic our a a antisense to placebo-controlled X portfolio, involving HBV. EDP-XXX, an inhibitor HBV model, agent activity compared quarter. candidate with be to trials our to to of study reasonably chronic Each patients evaluate production both core for where key NUCs antigen With the loads HBV new doses randomized Last this we as referred import next and a core destabilize a infected to reduction randomized announce evaluating the mouse RNAs stop of midyear. functional uncoating levels that HBV and to to lead opportunity in not we EDP-XXX can to replication as high placebo data viremic and of patients. selective mechanisms safety, currently of for component double-blind inhibit cure replication. excited shared see were compelling in take orally EDP-XXX and agents with administered clinical affects proteins by referred three nuclear to to newest several has plan at all-oral our oral month, model. siRNA designed virus they including proteins, are demonstrated replication are XX to EDP potential in of period and which based and effective viral inhibitor EDP-XXX new patients. to of to refer NUC-suppressed stages leads our of tested potent S-antigen. our forward destabilizer standard multiple a suppressing achieving HBV pharmacokinetics as move superior on of patients could S-antigen. and current HBV up RNA HBV candidate same inhibitor look in reduce the preliminary initiating as may expansion we Phase of recognize viral treated recycling. capsid HBV a also care in well chronic the now as which functional we
or NASH EDP-XXX The is randomized fibrosis. first resolution Phase steatohepatitis, double-blind non-alcoholic and/or on with Xb with subjects of Moving in our FXR without of XX-week of of to ongoing ARGON-X ARGON-X XXX endpoint work study our placebo-controlled biopsy-proven in without worsening NASH fibrosis. fibrosis is an improvement agonist approximately in NASH primary worsening NASH
have and mid-XXXX, which good internal ARGON-X, engagement we to an point in with combinations subset may were doses or dose also determine forward information one-milligram milligrams exploring favorably of tolerability dose a XX and we more we interim weeks to of partnering. tolerability. doses In dose for we ARGON-X additional potential While of expect analysis observed determine At treatment what of move target with X.X through target will or have X.X the engagement to patients. in are doses what with balance
tolerability We are in X tissue-targeted mid-XXXX. to first-in-human subjects. being approximately look healthy also effects. trial oral best-in-class to clinical our reporting adult designed It's We assess with in XX FXR and potentially double-blind studied potency and agonist currently Phase NASH data randomized follow-on in safety, placebo-controlled a for forward pharmacokinetics the EDP-XXX, developing
to and Enanta, EDP-XXX be emphasizing pipeline. to we important by and we optimal like will wholly key an year including Phase our expand Phase XXXX, conclude RNA points. few HBV both mid-XXXX, a destabilizer owned to assets the these positioned to catalysts EDP-XXX continue go-forward and in for study for time for So the in of anticipate active progress this prioritize look we my as several hMPV, remarks both Over insights our to initiation efforts, especially a forward I'd X Further, programs. It's been strategy. toward have define EDP-XXX the when two virology clinical expect we second RSV nominating looking discovery candidates respiratory SARS-CoV-X of clinical in by of mid-XXXX HBV study and quarter of X our EDP-XXX, new our and we among data patients preliminary XXXX. and
we EDP-XXX over quarter. study our forward insights of financials discuss look of the the midyear steps. trial and call I'll EDP-XXX, here for inform Finally, turn ARGON-X stop the in to Paul Phase NASH and to X to with Paul? to having valuable next the
